Log In
Print this Print this

ulocuplumab (BMS-936564) (formerly MDX-1338)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHuman IgG4 mAb against CXC chemokine receptor 4 (CXCR4; NPY3R)
Molecular Target CXC chemokine receptor 4 (CXCR4) (NPY3R)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat relapsed or refractory acute myelogenous leukemia (AML)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today